Structure via PubChem · Public domain (PubChem)
ebselen
Sign in to saveAlso known as DR3305, PZ 51, 2-phenyl-1,2-benzoselenazol-3-one
Ebselen (also called PZ 51, DR3305, and SPI-1005), is a synthetic organoselenium molecule under preliminary investigation as a drug candidate. It belongs to the class of compounds related to benzene and its derivatives. It is being developed by the Seattle biotechnology company, Sound Pharmaceuticals, Inc. It has also been reported to target tubulin, blocking its polymerization.
Chemical data
- Formula
- C13H9NOSe
- Molecular weight
- 274.19 g/mol
- IUPAC name
- 2-phenyl-1,2-benzoselenazol-3-one
- SMILES
- C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2
- InChIKey
- DYEFUKCXAQOFHX-UHFFFAOYSA-N
- Polar surface area
- 20.3 Ų
- H-bond donors
- 0
- H-bond acceptors
- 1
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- hearing loss, Meniere disease, ototoxicity, COVID-19
via ChEMBL · EBI
Research
1,414 papers- Ebselen improves fungal keratitis through exerting anti-inflammation, anti-oxidative stress, and antifungal effects.Redox biology · 2024
- Should ebselen be considered for the treatment of mercury intoxication? A minireview.Toxicology mechanisms and methods · 2024
- Mechanisms of ebselen as a therapeutic and its pharmacology applications.Future medicinal chemistry · 2020
- Antibacterial Activity of Ebselen.International journal of molecular sciences · 2023
- Ebselen.Methods in enzymology · 1995
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 274.985
Show 4 more facts
- canonical SMILES
- C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2
- chemical formula
- C₁₃H₉NOSe
- World Health Organisation international non-proprietary name
- ebselen
- Commons category
- Ebselen
via Wikidata · CC0
~2 min read
Encyclopedic overview
5 sectionsContents
- Synthesis
- History
- Research
- References
- External links
Ebselen (also called PZ 51, DR3305, and SPI-1005), is a synthetic organoselenium molecule under preliminary investigation as a drug candidate. It belongs to the class of compounds related to benzene and its derivatives. It is being developed by the Seattle biotechnology company, Sound Pharmaceuticals, Inc. It has also been reported to target tubulin, blocking its polymerization.
Ebselen has been entered into clinical trials as a lead compound intended for the potential treatment of various diseases. Its most advanced clinical trial is a Phase III study in people with Meniere's disease, completed in July 2024.
Excerpted from Wikipedia’s “ebselen” article, available under the CC BY-SA 4.0 licence.